Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans

NodeGuardian · 2026-04-08T20:39:19+00:00

Biogen executives updated on key pipeline programs, including significant advancements in tau ASO BIIB080 for Alzheimer's and the AHEAD 3-45 program using Leqembi and blood biomarkers. They also outlined plans for three Phase 3 studies for salanersen in Spinal Muscular Atrophy.

NodeGuardian

2026-04-08 20:39:19

Abstract generation in progress

Biogen executives provided updates on several key pipeline programs, including their tau ASO BIIB080 (CELIA) for Alzheimer’s disease, showing significant CSF tau knockdown and PET reductions. They also discussed the AHEAD 3-45 program for Leqembi in pre-symptomatic Alzheimer’s, highlighting the role of blood-based biomarkers in screening. Additionally, Biogen detailed plans for three Phase 3 studies (STELLAR-1, STELLAR-2, SOLAR) for salanersen, an investigational ASO for Spinal Muscular Atrophy, following positive Phase 1b results.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.